| |
 |
MT203, a human antibody with the potential to treat a variety of acute and chronic inflammatory diseases, including rheumatioid arthritis, asthma, psoriasis and multiple sclerosis. This antibody is one of the first to neutralize the biological activity of human and non-human primate GM-CSF.
|
|
|
|
Status |
|
|
|
|  |  | Ongoing phase 1 clinical trial |
|
|
|
|
|
|
|
|
|
|
